報價延遲最少15分鐘:2026/01/08 18:07 EST
盤後時段
|
||||
|
1.1897 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.18
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.12/-0.89
|
|
企業價值
159.77M
|
| 資產負債 |
|
每股賬面淨值
2.54
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
2.82M
|
|
每股收益
0.29
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. |
